share_log

Sabra Health Care REIT Analyst Ratings

Sabra Health Care REIT Analyst Ratings

Sabra 醫療保健房地產投資信託基金分析師評級
Benzinga ·  2023/07/14 11:31
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/14/2023 -1.5% Citigroup $11 → $12.5 Maintains Neutral
04/25/2023 2.44% Barclays $15 → $13 Maintains Equal-Weight
04/20/2023 -13.32% Wells Fargo → $11 Initiates Coverage On → Underweight
04/19/2023 -13.32% Wells Fargo → $11 Initiates Coverage On → Underweight
04/12/2023 2.44% Credit Suisse → $13 Reiterates → Neutral
03/29/2023 2.44% Truist Securities $14 → $13 Maintains Buy
03/28/2023 -17.26% Citigroup $13 → $10.5 Maintains Neutral
12/13/2022 — JMP Securities Downgrades Market Outperform → Market Perform
11/14/2022 2.44% B of A Securities $15 → $13 Downgrades Neutral → Underperform
10/10/2022 2.44% Baird → $13 Downgrades Outperform → Neutral
06/30/2022 10.32% Jefferies $15 → $14 Downgrades Buy → Hold
05/25/2022 18.2% Mizuho $16 → $15 Upgrades Neutral → Buy
04/18/2022 10.32% Barclays $16 → $14 Downgrades Overweight → Equal-Weight
04/04/2022 18.2% Credit Suisse $14 → $15 Maintains Neutral
03/11/2022 18.2% B of A Securities → $15 Upgrades Underperform → Neutral
02/23/2022 41.84% Stifel $21 → $18 Maintains Buy
02/18/2022 — Keybanc Initiates Coverage On → Sector Weight
02/01/2022 10.32% Credit Suisse → $14 Initiates Coverage On → Neutral
09/30/2021 41.84% Truist Securities → $18 Upgrades Hold → Buy
09/13/2021 57.6% JMP Securities $24 → $20 Maintains Market Outperform
05/21/2021 65.48% BMO Capital $20 → $21 Upgrades Market Perform → Outperform
05/10/2021 65.48% Stifel $17 → $21 Upgrades Hold → Buy
01/13/2021 57.6% Jefferies $17 → $20 Upgrades Hold → Buy
01/08/2021 49.72% BMO Capital → $19 Upgrades Underperform → Market Perform
12/03/2020 89.13% JMP Securities → $24 Upgrades Market Perform → Market Outperform
09/02/2020 18.2% Stifel → $15 Reinstates → Hold
06/23/2020 18.2% Scotiabank $12 → $15 Upgrades Sector Underperform → Sector Perform
06/22/2020 10.32% Wells Fargo $13 → $14 Maintains Equal-Weight
05/18/2020 18.2% Berenberg → $15 Upgrades Hold → Buy
04/23/2020 — SunTrust Robinson Humphrey Maintains Hold
04/07/2020 -21.2% Citigroup $20 → $10 Maintains Neutral
03/26/2020 -17.26% Wells Fargo $22 → $10.5 Maintains Equal-Weight
02/26/2020 73.36% Mizuho → $22 Upgrades Neutral → Buy
02/06/2020 97.01% Barclays $26 → $25 Maintains Overweight
02/05/2020 73.36% Berenberg → $22 Initiates Coverage On → Hold
12/20/2019 73.36% Mizuho → $22 Initiates Coverage On → Neutral
12/18/2019 — Citigroup Upgrades Sell → Neutral
10/14/2019 — B of A Securities Reinstates → Neutral
09/27/2019 81.25% JMP Securities $22 → $23 Maintains Market Outperform
09/23/2019 57.6% Citigroup $18 → $20 Downgrades Neutral → Sell
09/03/2019 89.13% Barclays → $24 Initiates Coverage On → Overweight
02/26/2019 — BMO Capital Downgrades Market Perform → Underperform
12/17/2018 49.72% Wells Fargo $23 → $19 Maintains Market Perform
11/16/2018 65.48% B of A Securities $23 → $21 Downgrades Neutral → Underperform
11/16/2018 — Raymond James Downgrades Outperform → Market Perform
11/13/2018 65.48% Mizuho → $21 Downgrades Buy → Neutral
09/19/2018 89.13% BMO Capital → $24 Initiates Coverage On → Market Perform
08/17/2018 89.13% Raymond James $22 → $24 Maintains Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
07/14/2023 -1.5% 花旗集團 $11→$12.5 維護 中性
04/25/2023 2.44% 巴克萊 $15→$13 維護 等重
04/20/2023 -13.32% 富國銀行 →$11 開始承保 →減持
04/19/2023 -13.32% 富國銀行 →$11 開始承保 →減持
04/12/2023 2.44% 瑞士信貸 →$13 重申 →中性
03/29/2023 2.44% Truist證券 $14→$13 維護 買
03/28/2023 -17.26% 花旗集團 $13→$10.5 維護 中性
2022年12月13日 - JMP證券 評級下調 市場表現優於→市場表現
2022年11月14日 2.44% B of A證券 $15→$13 評級下調 中性→表現不佳
2022年10月10日 2.44% 貝爾德 →$13 評級下調 跑贏→中性
2022/06/30 10.32% 傑富瑞 $15→$14 評級下調 購買→Hold
2022年05月25日 18.2% 瑞穗 $16→$15 升級 中性→購買
04/18/2022 10.32% 巴克萊 $16→$14 評級下調 超重→等重
04/04/2022 18.2% 瑞士信貸 $14→$15 維護 中性
03/11/2022 18.2% B of A證券 →$15 升級 表現不佳的→中性
02/23/2022 41.84% Stifel $21→$18 維護 買
02/18/2022 - KeyBanc 開始承保 →行業權重
02/01/2022 10.32% 瑞士信貸 →$14 開始承保 →中性
09/30/2021 41.84% Truist證券 →$18 升級 持有→購買
09/13/2021 57.6% JMP證券 $24→$20 維護 市場表現強於大盤
2021/05/21 65.48% 蒙特利爾銀行資本 $20→$21 升級 市場表現優於→
2021/05/10 65.48% Stifel $17→$21 升級 持有→購買
2021/01/13 57.6% 傑富瑞 $17→$20 升級 持有→購買
01/08/2021 49.72% 蒙特利爾銀行資本 →$19 升級 表現遜於→市場表現
12/03/2020 89.13% JMP證券 →$24 升級 市場表現優於→市場表現
09/02/2020 18.2% Stifel →$15 恢復 →保留
2020/06/23 18.2% 加拿大豐業銀行 $12→$15 升級 行業表現遜於→行業表現
06/22/2020 10.32% 富國銀行 $13→$14 維護 等重
05/18/2020 18.2% 貝倫伯格 →$15 升級 持有→購買
04/23/2020 - SunTrust Robinson Humphrey 維護 保持
04/07/2020 -21.2% 花旗集團 $20→$10 維護 中性
03/26/2020 -17.26% 富國銀行 $22→$10.5 維護 等重
02/26/2020 73.36% 瑞穗 →$22 升級 中性→購買
02/06/2020 97.01% 巴克萊 $26→$25 維護 超重
02/05/2020 73.36% 貝倫伯格 →$22 開始承保 →保留
2019年12月20日 73.36% 瑞穗 →$22 開始承保 →中性
2019年12月18日 - 花旗集團 升級 賣出→中性
2019年10月14日 - B of A證券 恢復 →中性
2019年09月27日 81.25% JMP證券 $22→$23 維護 市場表現強於大盤
2019年09月23日 57.6% 花旗集團 $18→$20 評級下調 中性→銷售
2019年09月03日 89.13% 巴克萊 →$24 開始承保 →超重
2019年02月26日 - 蒙特利爾銀行資本 評級下調 市場表現→表現不佳
2018年12月17日 49.72% 富國銀行 $23→$19 維護 市場表現
2018年11月16日 65.48% B of A證券 $23→$21 評級下調 中性→表現不佳
2018年11月16日 - 雷蒙德·詹姆斯 評級下調 跑贏→市場表現
2018年11月13日 65.48% 瑞穗 →$21 評級下調 購買→中性
2018年09月19日 89.13% 蒙特利爾銀行資本 →$24 開始承保 →市場表現
2018年08月17日 89.13% 雷蒙德·詹姆斯 $22→$24 維護 跑贏大盤

What is the target price for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的目標價格是多少？

The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by Citigroup on July 14, 2023. The analyst firm set a price target for $12.50 expecting SBRA to fall to within 12 months (a possible -1.50% downside). 10 analyst firms have reported ratings in the last year.

花旗集團於2023年7月14日報告了Sabra Health Care REIT(納斯達克：SBRA)的最新目標價。這家分析公司將目標價定為12.50美元，預計SBRA將在12個月內下跌(可能下跌1.50%)。去年有10家分析公司公佈了評級。

What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的最新分析師評級是多少？

The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by Citigroup, and Sabra Health Care REIT maintained their neutral rating.

花旗集團提供了對Sabra Health Care REIT(納斯達克代碼：SBRA)的最新分析師評級，Sabra Health Care REIT維持中性評級。

When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?

Sabra Health Care REIT(SBRA)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Sabra Health Care REIT的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sabra Health Care REIT的上一次評級是在2023年7月14日提交的，因此您應該預計下一次評級將在2024年7月14日左右的某個時候提供。

Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?

分析師對Sabra Health Care REIT(SBRA)的評級正確嗎？

While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a maintained with a price target of $11.00 to $12.50. The current price Sabra Health Care REIT (SBRA) is trading at is $12.69, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Sabra Health Care REIT(SBRA)評級保持不變，目標價在11.00美元至12.50美元之間。Sabra Health Care REIT(SBRA)目前的交易價格為12.69美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論